Main Industry
Biotechnology
Main Product/Service
Prodrug technology platform and novel cancer drug development. BY-101 has received Orphan Drug Designation from the US FDA, granting it 7 years of market exclusivity, and is applicable for the treatment of acute myeloid leukemia. BY-102 and BY-103 are patented drugs, which are respectively indicated for the treatment of multiple sclerosis and acute leukemia, among other indications.
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2010
Unified Business No.
53063165
Status
Active
Number of Employees
6
Total Paid-in
Capital
194,300,000 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2026)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
博研醫藥開發股份有限公司 was established in June 2010. In its initial stage, the company focused on novel drug research as its core, utilizing its proprietary prodrug synthesis technology platform to chemically modify existing generic small-molecule drugs to develop patented innovative drugs, striving to provide patients with new medical options while creating long-term, sustainable value for shareholders and stakeholders.
Through ten years of research and effort, the company has successfully established a prodrug technology platform. This platform can continuously support the research and development of new drugs and construct a diversified portfolio of drug candidates.
In addition, BY-101 obtained Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in January 2019. This "Orphan Drug Designation" by the U.S. Food and Drug Administration (FDA) is a special qualification specifically for drugs treating rare diseases, aimed at encouraging the pharmaceutical industry to develop therapeutic drugs needed by patients with rare diseases. Currently, the company's BY-101 has initiated Phase II clinical trials at three medical centers in Taiwan, and after obtaining drug approval in the future, BY-101 can enjoy a 7-year market exclusivity period. BY-102 and BY-103 are products of the company's prodrug technology platform, which are respectively applicable to the treatment of indications such as multiple sclerosis and acute leukemia.
The year 2020 was a key transition year for Boyan Pharmaceutical, transforming from an R&D unit originally focused primarily on novel drug research into a niche commercial company centered on clinical development, supplemented by research. In 2023, BY-101 entered U.S. FDA Phase 2/3 clinical trials through the 505(b)(2) pathway. BY-101 is a new therapeutic candidate drug for the indication of acute myeloid leukemia (AML). Currently, Phase II clinical trials (Phase 2b) have been initiated at three medical centers in Taiwan, with plans to enroll 15 newly diagnosed AML patients aged between 18 and 75. Subsequently, clinical progress and licensing cooperation opportunities will be further promoted. BY-102 is a brand-new candidate drug developed by Boyan using its proprietary prodrug technology platform. The project concept originated from the marketed oral tablet Mavenclad (a product of Merck, Germany). Addressing the issues of low absorption rate and related side effects faced by Mavenclad during administration, the Boyan team developed the patent-approved prodrug BY-102. It can stably convert into the active parent drug in vivo and, through powder micronization technology, effectively provides a next-generation oral treatment option with enhanced efficacy, greater convenience of administration, and lower side effects.
The company also actively explores cooperation with various domestic academic and research institutions to assist in introducing their research results into the drug development and clinical trial processes, creating greater value for domestic academic and research institutions diligently dedicated to biotechnology and novel drug research.
The company was approved as a biotechnology and new drug company by the Industrial Development Bureau of the Ministry of Economic Affairs in 2015 and 2024. The company's administrative office is located in the International Trade Building of the Taipei World Trade Center.
(The content above was translated by AI.)
Through ten years of research and effort, the company has successfully established a prodrug technology platform. This platform can continuously support the research and development of new drugs and construct a diversified portfolio of drug candidates.
In addition, BY-101 obtained Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in January 2019. This "Orphan Drug Designation" by the U.S. Food and Drug Administration (FDA) is a special qualification specifically for drugs treating rare diseases, aimed at encouraging the pharmaceutical industry to develop therapeutic drugs needed by patients with rare diseases. Currently, the company's BY-101 has initiated Phase II clinical trials at three medical centers in Taiwan, and after obtaining drug approval in the future, BY-101 can enjoy a 7-year market exclusivity period. BY-102 and BY-103 are products of the company's prodrug technology platform, which are respectively applicable to the treatment of indications such as multiple sclerosis and acute leukemia.
The year 2020 was a key transition year for Boyan Pharmaceutical, transforming from an R&D unit originally focused primarily on novel drug research into a niche commercial company centered on clinical development, supplemented by research. In 2023, BY-101 entered U.S. FDA Phase 2/3 clinical trials through the 505(b)(2) pathway. BY-101 is a new therapeutic candidate drug for the indication of acute myeloid leukemia (AML). Currently, Phase II clinical trials (Phase 2b) have been initiated at three medical centers in Taiwan, with plans to enroll 15 newly diagnosed AML patients aged between 18 and 75. Subsequently, clinical progress and licensing cooperation opportunities will be further promoted. BY-102 is a brand-new candidate drug developed by Boyan using its proprietary prodrug technology platform. The project concept originated from the marketed oral tablet Mavenclad (a product of Merck, Germany). Addressing the issues of low absorption rate and related side effects faced by Mavenclad during administration, the Boyan team developed the patent-approved prodrug BY-102. It can stably convert into the active parent drug in vivo and, through powder micronization technology, effectively provides a next-generation oral treatment option with enhanced efficacy, greater convenience of administration, and lower side effects.
The company also actively explores cooperation with various domestic academic and research institutions to assist in introducing their research results into the drug development and clinical trial processes, creating greater value for domestic academic and research institutions diligently dedicated to biotechnology and novel drug research.
The company was approved as a biotechnology and new drug company by the Industrial Development Bureau of the Ministry of Economic Affairs in 2015 and 2024. The company's administrative office is located in the International Trade Building of the Taipei World Trade Center.
(The content above was translated by AI.)
